In section Market Quotes

J&J Venture Arm Joins $100 Million Delix Therapeutics Funding

Johnson & Johnson’s venture capital arm and SV Health Investors’ Dementia Discovery Fund led a $100 million Series C round for Delix Therapeutics, which is developing versions of psychedelic compounds designed to avoid hallucinatory effects.

By Money Talk·November 9, 2026·2 min read·1,105 reads

J&J Venture Arm Joins $100 Million Delix Therapeutics Funding

Delix said the financing will support development of Zalsupindole through a Phase IIb proof-of-concept study in recurrent major depressive disorder. It will also fund the company’s broader neuroplastogen pipeline.

The company expects to start a Phase II trial in the first half of 2027.

J&J Venture Arm Joins $100 Million Delix Therapeutics Funding

Comments (0)